Earnings

Why You Should Want To Trade Titan Pharmaceuticals, Inc. (TTNP)

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of 45.89M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For TTNP, the company currently has 8.35 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 9.41 million in total assets, balanced by 1.88 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Titan Pharmaceuticals, Inc. (TTNP) saw -2.52 million in free cash flow last quarter, representing a quarterly net change in cash of -2.52 million. Perhaps most importantly where cash movements are concerned, the company saw about -2.52 million in net operating cash flow.



Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 77,000 in total revenues. That represents a quarterly year/year change in revenues of -1.00 in sequential terms, the TTNP saw sales decline by 0.00.

But what about the bottom line? After all, that’s what really matters in the end. Titan Pharmaceuticals, Inc. (TTNP) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 21.2 million, this means overall earnings per share of -0.17. Note, this compares with a consensus analyst forecast of -0.14 in earnings per share for its next fiscal quarterly report.




Is Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.41 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Titan Pharmaceuticals, Inc..

 

Previous ArticleNext Article

Related Post

Groupon, Inc. (GRPN) Internals Are Exhibiting Conf... Groupon, Inc. (NASDAQ:GRPN) gained 1.83% in yesterday’s session, going up from its prior closing price of $4.91 to $5.00, and has now recorded rally i...
Dissecting the Numbers for Sangamo Therapeutics, I... Sangamo Therapeutics, Inc. (NASDAQ:SGMO) and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) are the two most active stocks in the Biotechnology industry ...
Critical Comparison: Achaogen, Inc. (AKAO) vs. Ara... Achaogen, Inc. (NASDAQ:AKAO) shares are down more than -19.59% this year and recently decreased -0.33% or -$0.03 to settle at $10.44. Aratana Therapeu...
Choosing Between Sunrun Inc. (RUN) and Lattice Sem... Sunrun Inc. (NASDAQ:RUN) shares are up more than 9.79% this year and recently decreased -6.57% or -$0.41 to settle at $5.83. Lattice Semiconductor Cor...
Should You Buy BioMarin Pharmaceutical Inc. (BMRN)... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Bioverativ Inc. (NASDAQ:BIVV) are the two most active stocks in the Biotechnology industry based on tod...